Published in Arthritis Res on May 24, 2002
Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease. Genes Dev (2010) 1.21
Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int (2005) 0.83
Identification of autoimmune gene signatures in autism. Transl Psychiatry (2011) 0.80
Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacol Sin (2010) 0.79
Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med (2014) 0.76
The changing face of spondyloarthropathies under TNF α blockade. Open Rheumatol J (2008) 0.75
Design of a stable cell line producing a recombinant monoclonal anti-TNFα antibody based on a CHO cell line. Springerplus (2016) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J (1991) 8.31
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Still's disease in the adult. Ann Rheum Dis (1971) 4.58
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet (2001) 2.95
A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest (1999) 2.65
Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum (2001) 2.28
The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol (1993) 2.04
Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.86
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Thalidomide: current and potential clinical applications. Am J Med (2000) 1.81
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Patterns of cytokine production in psoriatic synovium. J Rheumatol (1998) 1.72
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol (2001) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol (2001) 1.47
Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut (2001) 1.47
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum (1984) 1.46
The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol (1996) 1.37
Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) 1.33
Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol (1997) 1.29
Cytokines in Behçet's disease. J Rheumatol (1996) 1.27
Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents (1998) 1.21
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol (1997) 1.16
Serum ferritin and isoferritins are tools for diagnosis of active adult Still's disease. J Rheumatol (1994) 1.14
Treatment of Behçet's disease--an update. Semin Arthritis Rheum (2001) 1.13
Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res (2000) 1.13
Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity. Clin Exp Dermatol (1994) 1.12
Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol (1998) 1.10
Tumor necrosis factor. J Am Acad Dermatol (1991) 1.01
Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol (1999) 1.01
Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol (1996) 0.98
Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (2000) 0.95
Adult onset Still's disease: clinical features and course. Clin Rheumatol (1992) 0.92
Increased serum ferritin levels in adult Still's disease. Lancet (1987) 0.87
Expression of tumor necrosis factor-alpha in muscles of polymyositis. J Neurol Sci (1997) 0.87
Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol (1996) 0.84
TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet (1998) 0.80
Therapeutic advances in ankylosing spondylitis. Expert Opin Investig Drugs (2001) 0.77
Psoriatic arthritis. Bull Rheum Dis (1995) 0.76